Daniel C. Edelman, Ph.D.
By developing and implementing state-of-the-art genomic technologies, the Clinical Molecular Profiling Core (CMPC) maximizes the clinical benefits and biological insights derived from the analysis of biospecimens obtained from NCI clinical trials. To stay current with developing technologies, the Core includes a research and development component as part of its mission to innovate and develop new, cutting-edge applications that widen the applicability of genome technologies to clinically accessible samples.
The CMPC Mission By developing and implementing state of the art genomic technologies, the Clinical Molecular Profiling Core maximizes the clinical benefits and biological insights derived from the analysis of biospecimens obtained from National Cancer Institutes clinical trials. Core Activities: Research & Clinical (CLIA) The Clinical Molecular Profiling Core (CMPC) was established in 2006 under the auspices of the Center for Cancer Research, National Cancer Institute. The vision was to create a robust and scientifically advanced laboratory program that would bring the tools of genome technology to bear on NCI intramural clinical trials. It has become increasingly recognized in this new era of targeted therapies that critical aspects of tumor biology can be elucidated by analysis of the cancer genome. Clinical trial outcomes could be better characterized with analysis of cancer genomes with respect to properties such as copy number aberrations, epigenomics, mRNA, and micro-RNA profiles. Importantly, these data also can drive discovery of new tumor subsets and therapeutically relevant genomic features which can lead to personalized cancer treatments. The CMPC creates the opportunity to make the necessary molecular analyses available to any NCI clinical investigator. Being a CLIA compliant laboratory magnifies our impact which allows us to raise the bar on personalized cancer medicine. In order to keep CMPC technologies at the state-of-the-art, the Core includes a technology research and development component in its mission to innovate and develop new cutting edge applications that would widen the applicability of genome technologies to clinically accessible samples.
Genome-wide methylation patterns in papillary thyroid cancer are distinct based on histological subtype and tumor genotype.J. Clin. Endocrinol. Metab.. 99: E329-37, 2014. [ Journal Article ]
- Nat. Genet.. 46: 41861, 2014. [ Journal Article ]
Integrated analysis of genome-wide methylation and gene expression shows epigenetic regulation of CYP11B2 in aldosteronomas.J. Clin. Endocrinol. Metab.. 99: E536-43, 2014. [ Journal Article ]
- J. Clin. Invest.. 124: 398-412, 2014. [ Journal Article ]
- Nat. Genet.. 46: 844-9, 2014. [ Journal Article ]
|Tai Chi Cheuk Ph.D.||Senior Scientist (Contr)|
|J. Keith Killian M.D., Ph.D.||Staff Clinician|
|David Petersen||Research Biologist|
|Marbin Pineda||Research Biologist|
|Jennifer L. Walling M.S.||Research Biologist|
|Yonghong Wang Ph.D.||Research Biologist|